CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications

mAbs

Volumn 8, Issue 5, 2016, Pages 867-878

  Steinmetz, Anke ^b   Vallée, François ^b   Beil, Christian ^a   Lange, Christian ^a   Baurin, Nicolas ^b,c   Beninga, Jochen ^a   Capdevila, Cécile ^b   Corvey, Carsten ^a   Dupuy, Alain ^b   Ferrari, Paul ^b   Rak, Alexey ^b   Wonerow, Peter ^a   Kruip, Jochen ^a   Mikol, Vincent ^b   Rao, Ercole ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b SANOFI   (France)

^c SANOFI PASTEUR   (France)

Author keywords

ADCC; bispecific biotherapeutics; bivalent immunoglobulin; CDC; CODV Fab crystal structure; protein design; protein protein docking; T cell engager; tetravalent format

Indexed keywords

CROSS OVER DUAL VARIABLE IG LIKE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; IMMUNOGLOBULIN; SOMATOMEDIN C RECEPTOR; TETRAVIL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY;

ANTIBODY COMBINING SITE; ANTIGEN BINDING; ARTICLE; BIOCHEMICAL ANALYSIS; BIOPHYSICS; CRYSTALLOGRAPHY; CYTOTOXICITY; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; OLIGOMERIZATION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; BIOSYNTHESIS; DRUG DESIGN; HUMAN; MOLECULAR MODEL; PROCEDURES; PROTEIN ENGINEERING;

ANTIBODIES, BISPECIFIC; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PROTEIN ENGINEERING;

EID: 84963542010     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1162932     Document Type: Article

References (98)

1. R.Kontermann. Dual targeting strategies with bispecific antibodies. Mabs 2012; 4:182-97; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
2. J.S.Marvin, Z.Zhu. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 2005; 26:649-58; PMID:15916729; http://dx.doi.org/10.1111/j.1745-7254.2005.00119.x
3. C.Bokemeyer. Catumaxomab - trifunctional anti-EpCAM antibody used to treat malignant ascites. Expert Opin Biol Ther 2010; 10:1259-69; PMID:20624115; http://dx.doi.org/10.1517/14712598.2010.504706
4. E.Dhimolea, J.M.Reichert. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. Mabs 2012; 4:4-13; PMID:22327426; http://dx.doi.org/10.4161/mabs.4.1.18821
5. F.Unverdorben, A.Färber-Schwarz, F.Richter, M.Hutt, R.E.Kontermann. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A. Protein Eng Des Sel 2012; 25:81-88; PMID:22238430; http://dx.doi.org/10.1093/protein/gzr061
6. D.Müller, A.Karle, B.Meissburger, I.Höfig, R.Stork, R.E.Kontermann. Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin. J Biol Chem 2007; 282:12650-60; PMID:17347147; http://dx.doi.org/10.1074/jbc.M700820200
7. P.Holliger, M.Wing, J.D.Pound, H.Bohlen, G.Winter. Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol 1997; 15:632-36; PMID:9219264; http://dx.doi.org/10.1038/nbt0797-632
8. T.S.Von Kreudenstein, E.Escobar-Carbrera, P.I.Lario, I.D'Angelo, K.Brault, J.F.Kelly, Y.Durocher, J.Baardsnes, R.J.Woods, M.H.Xie, et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability. mAbs 2013; 5:646-54; PMID:23924797; http://dx.doi.org/10.4161/mabs.25632
9. Y.Reiter, U.Brinkmann, B.Lee, I.Pastan. Engineering antibody Fv fragments for cancer detection and therapy: Bisulfide-stabilized Fv fragments. Nat Biotechnol 1996; 14:1239-45; PMID:9631086; http://dx.doi.org/10.1038/nbt1096-1239
10. R.Raag, M.Whitlow. Single-chain Fvs. FASEB J 1995; 9:73-80; PMID:7821762
11. D.Röthlisberger, A.Honegger, A.Plückthun. Domain interactions in the Fab fragment: A comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005; 347:773-89; PMID:15769469; http://dx.doi.org/10.1016/j.jmb.2005.01.053
12. A.Wörn, A.Plückthun. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001; 305:989-1010; PMID:11162109; http://dx.doi.org/10.1006/jmbi.2000.4265
13. S.Fenn, C.B.Schiller, J.J.Griese, H.Duerr, S.Imhof-Jung, C.Gassner, J.Moelleken, J.T.Regula, W.Schaefer, M.Thomas, et al. Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain. PloS One 2013; 8:e61953; PMID:23613981; http://dx.doi.org/10.1371/journal.pone.0061953
14. Y.Mazor, V.Oganesyan, C.Yang, A.Hansen, J.Wang, H.Liu, K.Sachsenmeier, M.Carlson, D.V.Gadre, M.J.Borrok, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. mAbs 2015; 7:377-89; PMID:25621507; http://dx.doi.org/10.1080/19420862.2015.1007816
15. P.Carter. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15; PMID:11223065; http://dx.doi.org/10.1016/S0022-1759(00)00339-2
16. J.H.Davis, C.Aperlo, Y.Li, E.Kurosawa, Y.Lan, K.M.Lo, J.S.Huston. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195-202; PMID:20299542; http://dx.doi.org/10.1093/protein/gzp094
17. K.Gunasekaran, M.Pentony, M.Shen, L.Garrett, C.Forte, A.Woodward, S.B.Ng, T.Born, M.Retter, K.Manchulenko, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J BiolChem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc.M110.117382
18. W.Schaefer, J.T.Regula, M.Bähner, J.Schanzer, R.Croasdale, H.Dürr, C.Gassner, G.Georges, H.Kettenberger, S.Imhof-Jung, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
19. S.M.Lewis, X.Wu, A.Pustilnik, A.Sereno, F.Huang, H.L.Rick, G.Guntas, A.Leaver-Fay, E.M.Smith, C.Ho, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotech 2014; 32:191-8; PMID:24463572; http://dx.doi.org/10.1038/nbt.2797
20. C.Spiess, M.Merchant, A.Huang, Z.Zheng, N.Y.Yang, J.Peng, D.Ellerman, W.Shatz, D.Reilly, D.G.Yansura, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotech 2013; 31:753-8; PMID:23831709; http://dx.doi.org/10.1038/nbt.2621
21. X.Wu, A.J.Sereno, F.Huang, K.Zhang, M.Batt, J.R.Fitchett, D.He, H.L.Rick, E.M.Conner, S.J.Demarest. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. Mabs 2015; 7:364-76; PMID:25611120; http://dx.doi.org/10.1080/19420862.2015.1007826
22. X.Wu, A.J.Sereno, F.Huang, S.M.Lewis, R.L.Lieu, C.Weldon, C.Torres, C.Fine, M.A.Batt, J.R.Fitchett, et al. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. Mabs 2015; 7:470-82; PMID:25774965; http://dx.doi.org/10.1080/19420862.2015.1007826
23. C.Wu, H.Ying, C.Grinnell, S.Bryant, R.Miller, A.Clabbers, S.Bose, D.McCarthy, R.R.Zhu, L.Santora, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotech 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
24. E.L.DiGiammarino, J.E.Harlan, K.A.Walter, U.S.Ladror, R.P.Edalji, C.W.Hutchins, M.R.Lake, A.J.Greischar, J.Liu, T.Ghayur, et al. Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design. Mabs 2001; 3:487-94; PMID:21814039; http://dx.doi.org/10.4161/mabs.3.5.16326
25. E.Rao, V.Mikol, D.Li, J.Kruip, M.Davison. Humanized antibodies that bind interleukin-4 and/or interleukin-13 WO 2009052081 A2
26. I.Correia, J.Sung, R.Burton, C.G.Jakob, B.Carragher, T.Ghayur, C.Radziejewski. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen. Mabs 2013; 5:364-72; PMID:23572180; http://dx.doi.org/10.4161/mabs.24258
27. C.G.Jakob, R.Edalji, R.A.Judge, E.DiGiammarino, Y.Li, J.Gu, T.Ghayur. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig) molecule. Mabs 2013; 5:358-63; PMID:23549062; http://dx.doi.org/10.4161/mabs.23977
28. C.Wu. Diabodies: Molecular engineering and therapeutic applications. Drug News Perspect 2009; 22:453-8; PMID:20016854
29. G.R.Chichili, L.Huang, H.Li, S.Burke, L.He, Q.Tang, L.Jin, S.Gorlatov, V.Ciccarone, F.Chen, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates. Sci Transl Med 2015; 7:289ra82; PMID:26019218; http://dx.doi.org/10.1126/scitranslmed.aaa5693
30. D.Bumbaca, C.A.Boswell, P.J.Fielder, L.A.Khawli. Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics. AAPS J 2012; 14:554-8; PMID:22610647; http://dx.doi.org/10.1208/s12248-012-9369-y
31. D.T.Kamei, B.J.Lao, M.S.Ricci, R.Deshpande, H.Xu, B.Tidor, D.A.Lauffenburger. Quantitative methods for developing Fc mutants with extended half-lives. Biotechnol Bioeng 2005; 92:748-60; PMID:16136591; http://dx.doi.org/10.1002/bit.20624
32. T.T.Kuo, K.Baker, M.Yoshida, S.W.Qiao, V.G.Aveson, W.Lencer, R.S.Blumberg. Neonatal Fc Receptor: From Immunity to Therapeutics. J Clin Immunol 2010; 30:777-89; PMID:20886282; http://dx.doi.org/10.1007/s10875-010-9468-4
33. D.C.Roopenian, V.Z.Sun. Clinical Ramifications of the MHC Family Fc Receptor FcRn. J Clin Immunol 2010; 30:790-7; PMID:20848168; http://dx.doi.org/10.1007/s10875-010-9458-6
34. L.L.Sun, D.Ellerman, M.Mathieu, M.Hristopoulos, X.Chen, Y.Li, X.Yan, R.Clark, A.Reyes, E.Stefanich, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med 2015; 287ra70; PMID:25972002; http://dx.doi.org/10.1126/scitranslmed.aaa4802
35. Y.N.Abdiche, Y.A.Yeung, J.Chaparro-Riggers, I.Barman, P.Strop, S.M.Chin, A.Pham, G.Bolton, D.McDonough, K.Lindquist, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. mAbs 2015; 7:331-43; PMID:25658443; http://dx.doi.org/10.1080/19420862.2015.1008353
36. D.Dornan, O.Spleiss, R.F.Yeh, G.Duchateau-Nguyen, A.Dufour, J.Zhi, T.Robak, S.I.Moiseev, A.Dmoszynska, P.Solal-Celigny, et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood 2010; 116:4212-22; PMID:20705761; http://dx.doi.org/10.1182/blood-2010-03-272765
37. J.O.Richards, S.Karki, G.A.Lazar, H.Chen, W.Dang, J.R.Desjarlais. Optimization of antibody binding to FcgRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7:2517-27; PMID:18723496; http://dx.doi.org/10.1158/1535-7163.MCT-08-0201
38. M.A.Ströhlein, M.M.Heiss. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis. Future Oncol 2010; 6:1387-94; PMID:20919824; http://dx.doi.org/10.2217/fon.10.111
39. E.C.Piccione, S.Juarez, J.Liu, S.Tseng, C.E.Ryan, C.Narayanan, L.Wang, K.Weiskopf, R.Majeti. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. Mabs 2015; 7:946-56; PMID:26083076; http://dx.doi.org/10.1080/19420862.2015.1062192
40. C.A.Diebolder, F.J.Beurskens, R.N.de Jong, R.I.Koning, K.Strumane, M.A.Lindorfer, M.Voorhorst, D.Ugurlar, S.Rosati, A.J.R.Heck, et al. Complement Is Activated by IgG Hexamers Assembled at the Cell Surface. Sci 2014; 343:1260-3; PMID:24626930; http://dx.doi.org/10.1126/science.1248943
41. W.Wang, E.Wang, J.Balthasar. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics. Clin Pharmacol Therapeutics 2008; 84:548-58; http://dx.doi.org/10.1038/clpt.2008.170
42. I.Sela-Culang, V.Kunik, Y.Ofran. The structural basis of antibody-antigen recognition. Front Immunol 2013; 4:302; PMID:24115948; http://dx.doi.org/10.3389/fimmu.2013.00302
43. I.Sela-Culang, S.Alon, Y.Ofran. A systematic comparison of free and bound antibodies reveals binding-related conformational changes. J Immunol 2012; 189:4890-9; PMID:23066154; http://dx.doi.org/10.4049/jimmunol.1201493
44. K.Masuda, K.Sakamoto, M.Kojima, T.Aburatani, T.Ueda, H.Ueda. The role of interface framework residues in determining antibody VH/VL interaction strength and antigen-binding affinity. FEBS J 2006; 273:2184-94; PMID:16649995; http://dx.doi.org/10.1111/j.1742-4658.2006.05232.x
45. M.E.Birnbaum, R.Berry, Y.S.Hsiao, Z.Chen, M.A.Shingu-Vazquez, X.Yu, D.Waghray, S.Fischer, J.McCluskey, J.Rossjohn, et al. Molecular architecture of the ab T cell receptor-CD3 complex. PNAS USA 2014; 111:17576-81; PMID:25422432; http://dx.doi.org/10.1073/pnas.1420936111
46. I.A.Haagen, R.van de Griend, M.Clark, A.Geerars, B.Bast, B.de Gast. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (aCD3/aCD19). Clin Exp Immunol 1992; 90:368-75; PMID:1281055; http://dx.doi.org/10.1111/j.1365-2249.1992.tb05853.x
47. M.Mack, G.Riethmüller, P.Kufer. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. PNAS USA 1995; 92:7021-5; PMID:7624362; http://dx.doi.org/10.1073/pnas.92.15.7021
48. C.H.Kim, J.Y.Axup, B.R.Lawson, H.Yun, V.Tardif, S.H.Choi, Q.Zhou, A.Dubrovska, S.L.Biroc, R.Marsden, et al. Bispecific small molecule-antibody conjugate targeting prostate cancer. PNAS USA 2013; 110:17796-801; PMID:24127589; http://dx.doi.org/10.1073/pnas.1316026110
49. M.Hirvinen, R.Heiskanen, M.Oksanen, S.Pesonen, I.Liikanen, T.Joensuu, A.Kanerva, V.Cerullo, A.Hemminki. Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. J Transl Med 2013; 11:1-12; PMID:23281771; http://dx.doi.org/10.1186/1479-5876-11-193
50. P.Sondermann, R.Huber, U.Jacob. Crystal structure of the soluble form of the human fcgamma-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution. EMBO J 1999; 18:1095-103; PMID:10064577; http://dx.doi.org/10.1093/emboj/18.5.1095
51. P.Sondermann, J.Kaiser, U.Jacob. Molecular basis for immune complex recognition: A comparison of Fc-receptor structures. J Mol Biol 2001; 309:737-49; PMID:11397093; http://dx.doi.org/10.1006/jmbi.2001.4670
52. M.Raghavan, P.J.Bjorkman. Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 1996; 12:181-220; PMID:8970726; http://dx.doi.org/10.1146/annurev.cellbio.12.1.181
53. W.P.Burmeister, A.H.Huber, P.J.Bjorkman. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nat 1994; 372:379-83; PMID:7969498; http://dx.doi.org/10.1038/372379a0
54. Merrimack. MM-111 Phase 2 trial. http://www.merrimackpharma.com/pipeline/mm-111/mm-111-phase-2-trial (Access Date February3, 2015) (2015)
55. C.M.Warren, R.Landgraf. Signaling through ERBB receptors: Multiple layers of diversity and control. Cell Signal 2006; 18:923-33; PMID:16460914; http://dx.doi.org/10.1016/j.cellsig.2005.12.007
56. M.Blaber, J.Lee. Designing proteins from simple motifs: opportunities in Top-Down Symmetric Deconstruction. Curr Opin Struct Biol 2012; 22:442-50; PMID:22726756; http://dx.doi.org/10.1016/j.sbi.2012.05.008
57. A.Urvoas, M.Valerio-Lepiniec, P.Minard. Artificial proteins from combinatorial approaches. Trends Biotechnol 2012; 30:512-20; PMID:22795485; http://dx.doi.org/10.1016/j.tibtech.2012.06.001
58. N.Sawyer, J.Chen, L.Regan. All repeats are not equal: A module-based approach to guide repeat protein design. J Mol Biol 2013; 425:1826-38; PMID:23434848; http://dx.doi.org/10.1016/j.jmb.2013.02.013
59. N.Sawyer, E.B.Speltz, L.Regan. NextGen protein design. Biochem Soc Trans 2013; 41:1131-6; PMID:24059497; http://dx.doi.org/10.1042/BST20130112
60. M.Merkx, M.V.Golynskiy, L.H.Lindenburg, J.L.Vinkenborg. Rational design of FRET sensor proteins based on mutually exclusive domain interactions. Biochem Soc Trans 2013; 41:1201-5; PMID:24059509; http://dx.doi.org/10.1042/BST20130128
61. J.Huang, A.Koide, K.Makabe, S.Koide. Design of protein function leaps by directed domain interface evolution. PNAS USA 2008; 105:6578-83; PMID:18445649; http://dx.doi.org/10.1073/pnas.0801097105
62. X.Zhou, H.Wang, Y.Zhang, L.Gao, Y.Feng. Alteration of substrate specificities of thermophilic α/β hydrolases through domain swapping and domain interface optimization. Acta Biochim Biophys Sin (Shanghai) 2012; 44:965-73; PMID:23099882; http://dx.doi.org/10.1093/abbs/gms086
63. A.Broom, A.C.Doxey, Y.D.Lobsanov, L.G.Berthin, D.R.Rose, P.L.Howell, B.J.McConkey, E.M.Meiering. Modular evolution and the origins of symmetry: Reconstruction of a 3-fold symmetric globular protein. Structure 2012; 20:161-71; PMID:22178248; http://dx.doi.org/10.1016/j.str.2011.10.021
64. I.Yadid, D.S.Tawfik. Functional β-propeller lectins by tandem duplications of repetitive units. Protein Eng Des Sel 2011; 24:185-95; PMID:20713410; http://dx.doi.org/10.1093/protein/gzq053
65. A.R.D.Voet, H.Noguchi, C.Addy, D.Simoncini, D.Terada, S.Unzai, S.Y.Park, K.Y.J.Zhang, J.R.H.Tame. Computational design of a self-assembling symmetrical β-propeller protein. PNAS USA 2014; 111:15102-7; PMID:25288768; http://dx.doi.org/10.1073/pnas.1412768111
66. M.F.Lensink, S.J.Wodak. Docking, scoring, and affinity prediction in CAPRI. Proteins 2013; 81:2082-95; PMID:24115211; http://dx.doi.org/10.1002/prot.24428
67. I.H.Moal, M.Torchala, P.A.Bates, J.Fernández-Recio. The scoring of poses in protein-protein docking: current capabilities and future directions. BMC Bioinformatics 2013; 14:1-15; PMID:23323762; http://dx.doi.org/10.1186/1471-2105-14-286
68. Y.Mazor, A.Hansen, C.Yang, P.S.Chowdhury, J.Wang, G.Stephens, H.Wu, W.F.Dall'Acqua. Insights into the molecular basis of a bispecific antibody's target selectivity. Mabs 2015; 7:461-9; PMID:25730144; http://dx.doi.org/10.1080/19420862.2015.1022695
69. J.Wang, S.Iyer, P.J.Fielder, J.D.Davis, R.Deng. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. Biopharm Drug Dispos 2015
70. T.Ying, Y.Wang, Y.Feng, P.Prabakaran, R.Gong, L.Wang, K.Crowder, D.S.Dimitrov. Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. Mabs 2015; 7:922-30; PMID:26179052; http://dx.doi.org/10.1080/19420862.2015.1067353
71. A.Datta-Mannan, C.K.Chow, C.Dickinson, D.Driver, J.Lu, D.R.Witcher, V.J.Wroblewski. FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys. Drug Metab Dispos 2012; 40:1545-55; PMID:22584253; http://dx.doi.org/10.1124/dmd.112.045864
72. M.Jäger, A.Schoberth, P.Ruf, J.R.Hess, H.Lindhofer. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res 2009; 69:4270-6; PMID:19435924; http://dx.doi.org/10.1158/0008-5472.CAN-08-2861
73. S.Diermeier-Daucher, O.Ortmann, S.Buchholz, G.Brockhoff. Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. Mabs 2012; 4:614-22; PMID:22820509; http://dx.doi.org/10.4161/mabs.21003
74. J.L.Teeling, R.R.French, M.S.Cragg, J.van den Brakel, M.Pluyter, H.Huang, C.Chan, P.W.H.I.Parren, C.E.Hack, M.Dechant, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104:1793-800; PMID:15172969; http://dx.doi.org/10.1182/blood-2004-01-0039
75. M.de Weers, Y.T.Tai, M.S.van der Veer, J.M.Bakker, T.Vink, D.C.H.Jacobs, L.A.Oomen, M.Peipp, T.Valerius, J.W.Slootstra, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186:1840-8; PMID:21187443; http://dx.doi.org/10.4049/jimmunol.1003032
76. P.Sondermann, R.Huber, V.Oosthuizen, U.Jacob. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcgRIII complex. Nat 2000; 406:267-73; http://dx.doi.org/10.1038/35018508
77. G.A.Lazar, W.Dang, S.Karki, O.Vafa, J.S.Peng, L.Hyun, C.Chan, H.S.Chung, A.Eivazi, S.C.Yoder, et al. Engineered antibody Fc variants with enhanced effector function. PNAS USA 2006; 103:4005-10; PMID:16537476; http://dx.doi.org/10.1073/pnas.0508123103
78. F.Mimoto, S.Kadono, H.Katada, T.Igawa, T.Kamikawa, K.Hattori. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcgRs. Mol Immunol 2014; 58:132-38; PMID:24334029; http://dx.doi.org/10.1016/j.molimm.2013.11.017
79. F.Mimoto, T.Igawa, T.Kuramochi, H.Katada, S.Kadono, T.Kamikawa, M.Shida-Kawazoe, K.Hattori. Novel asymmetrically engineered antibody Fc variant with superior Fc gamma R binding affinity and specificity compared with afucosylated Fc variant. mAbs 2013; 5:229-36; PMID:23406628; http://dx.doi.org/10.4161/mabs.23452
80. D.A.Haake, E.C.Franklin, B.Frangione. The modification of human immunoglobulin binding to staphylococcal protein A using diethylpyrocarbonate. J Immunol 1982; 129:190-2; PMID:6211482
81. J.Deisenhofer. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-.ANG. resolution. Biochem 1981; 20:2361-70; PMID:7236608; http://dx.doi.org/10.1021/bi00512a001
82. M.Sasano, D.R.Burton, G.J.Silverman. Molecular selection of human antibodies with an unconventional bacterial B cell antigen. J Immunol 1993; 151:5822-39; PMID:8228264
83. E.H.Sasso, G.J.Silverman, M.Mannik. Human IgM molecules that bind staphylococcal protein A contain VHIII H chains. J Immunol 1989; 142:2778-83; PMID:2495325
84. E.H.Sasso, G.J.Silverman, M.Mannik. Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup. J Immunol 1991; 147:1877-83; PMID:1909733
85. J.T.Nelson, S.Kim, N.F.Reuel, D.P.Salem, G.Bisker, M.P.Landry, S.Kruss, P.W.Barone, S.Kwak, M.S.Strano. Mechanism of Immobilized Protein A Binding to Immunoglobulin G on Nanosensor Array Surfaces. Anal Chem 2015; 87:8186-93; PMID:26149633; http://dx.doi.org/10.1021/acs.analchem.5b00843
86. H.Ogi, K.Motohisa, K.Hatanaka, T.Ohmori, M.Hirao, M.Nishiyama. Concentration dependence of IgG-protein A affinity studied by wireless-electrodeless QCM. Biosens Bioelectron 2007; 22:3238-42; PMID:17420120; http://dx.doi.org/10.1016/j.bios.2007.03.003
87. K.Saha, F.Bender, E.Gizeli. Comparative study of IgG binding to proteins G and A: Nonequilibrium kinetic and binding constant deetermination with the acoustic waveguide device. Anal Chem 2003; 75:835-42; PMID:12622374; http://dx.doi.org/10.1021/ac0204911
88. L.N.Deis, Q.Wu, Y.Wang, Y.Qi, K.G.Daniels, P.Zhou, T.G.Oas. Suppression of conformational heterogeneity at a protein-protein interface. PNAS USA 2015; 112:9028-33; PMID:26157136; http://dx.doi.org/10.1073/pnas.1424724112
89. M.Graille, E.A.Stura, A.L.Corper, B.J.Sutton, M.J.Taussig, J.B.Charbonnier, G.J.Silverman. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: Structural basis for recognition of B-cell receptors and superantigen activity. PNAS USA 2000; 97:5399-404; PMID:10805799; http://dx.doi.org/10.1073/pnas.97.10.5399
90. J.M.Donaldson, C.Zer, K.N.Avery, K.P.Bzymek, D.A.Horne, J.C.Williams. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies. PNAS USA 2013; 110:17456-61; PMID:24101516; http://dx.doi.org/10.1073/pnas.1307309110
91. S.G.Madhavi, M.Adzhigirey, T.Day, R.Annabhimoju, W.Sherman. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 2013; 27:221-34; PMID:23579614; http://dx.doi.org/10.1007/s10822-013-9644-8
92. M.P.Jacobson, R.A.Friesner, Z.Xiang, B.Honig. On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol 2002; 320:597-608; PMID:12096912; http://dx.doi.org/10.1016/S0022-2836(02)00470-9
93. M.P.Jacobson, D.L.Pincus, C.S.Rapp, T.J.F.Day, B.Honig, D.E.Shaw, R.A.Friesner. A hierarchical approach to all-atom protein loop prediction. Proteins 2004; 55:351-67; PMID:15048827; http://dx.doi.org/10.1002/prot.10613
94. Z.Guo, U.Mohanty, J.Noehre, T.K.Sawyer, W.Sherman, G.Krilov. Probing the a-helical structural stability of stapled p53 peptides: Molecular dynamics simulations and analysis. Chem Biol Drug Des 2010; 75:348-59; PMID:20331649; http://dx.doi.org/10.1111/j.1747-0285.2010.00951.x
95. Schrödinger. Schrödinger Release 2014-4: Maestro, version 10.0, New York, NY: Schrödinger, LLC (2014) 2015
96. R.Chen, Z.Weng. Docking unbound proteins using shape complementarity, desolvation, and electrostatics. Proteins 2002; 47:281-94; PMID:11948782; http://dx.doi.org/10.1002/prot.10092
97. B.G.Pierce, Y.Hourai, Z.Weng. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS One 2011; 6:e24657 EP; PMID:21949741; http://dx.doi.org/10.1371/journal.pone.0024657
98. Dassault Systèmes BIOVIA. Discovery Studio Modeling Environment, Release 2011, San Diego: Dassault Systèmes (2011)